Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0080188 |
| Name | chronic myelomonocytic leukemia |
| Definition | A chronic leukemia characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Xrefs |
ICDO:9945/3
|
| Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia chronic leukemia chronic myelomonocytic leukemia |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|---|---|---|---|
| FLT3 exon 14 ins FLT3 A848P | Sorafenib + Sunitinib | chronic myelomonocytic leukemia | predicted - resistant | detail... |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01773395 | Phase II | Busulfan + Fludarabine + Methotrexate + Tacrolimus Busulfan + Fludarabine + GVAX + Methotrexate + Tacrolimus | GVAX vs. Placebo for MDS/AML After Allo HSCT | Terminated | USA | 0 |
| NCT01787487 | Phase II | Azacitidine + Ruxolitinib | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Active, not recruiting | USA | 0 |
| NCT02193958 | Phase Ib/II | FF-10501-01 | Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies | Completed | USA | 0 |
| NCT02268253 | Phase II | Tagraxofusp-erzs | Tagraxofusp (SL-401) in Patients With CMML or MF | Completed | USA | CAN | 0 |
| NCT02530034 | Phase I | Hu8F4 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | Active, not recruiting | USA | 0 |
| NCT02546284 | Phase I | LAM-003 | Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) | Completed | USA | 0 |
| NCT02717884 | Phase Ib/II | Cytarabine + Tranylcypromine + Tretinoin | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) (TRANSATRA) | Unknown status | DEU | 0 |
| NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
| NCT02749708 | Phase Ib/II | IRX5183 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | Terminated | USA | 0 |
| NCT02841540 | Phase I | H3B-8800 | A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia | Terminated | USA | ITA | FRA | ESP | BEL | 2 |
| NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
| NCT03047993 | Phase Ib/II | Azacitidine + Telaglenastat | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | Completed | USA | 0 |
| NCT03263637 | Phase I | AZD4573 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Completed | NLD | GBR | DEU | 0 |
| NCT03268954 | Phase III | Azacitidine + MLN4924 Azacitidine | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER) | Completed | USA | TUR | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | 5 |
| NCT03289910 | Phase II | Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | Active, not recruiting | USA | 0 |
| NCT03306264 | Phase III | Decitabine Decitabine and Cedazuridine | Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML | Completed | USA | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | AUT | 0 |
| NCT03326921 | Phase I | Cyclophosphamide + Fludarabine HA-1 TCR T cells | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | Recruiting | USA | 0 |
| NCT03358719 | Phase I | Decitabine + Nivolumab + Poly ICLC + Rasdegafusp alfa | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | USA | 0 |
| NCT03383575 | Phase II | Azacitidine + Enasidenib Enasidenib | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | Recruiting | USA | 0 |
| NCT03386513 | Phase Ib/II | IMGN632 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 0 |
| NCT03404193 | Phase II | Decitabine + Venetoclax | Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
| NCT03404726 | Phase I | BAY2402234 | A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies | Terminated | USA | FRA | 0 |
| NCT03515512 | Phase I | Enasidenib | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
| NCT03531736 | Phase I | Rituximab Cyclophosphamide + Fludarabine | T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | Active, not recruiting | USA | 0 |
| NCT03564821 | Phase I | Ivosidenib | IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
| NCT03613532 | Phase I | Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | Active, not recruiting | USA | 0 |
| NCT03614728 | Phase I | Azacitidine + GSK3326595 GSK3326595 | Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | Terminated | USA | CAN | 0 |
| NCT03670966 | Phase Ib/II | BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus | 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome | Recruiting | USA | 0 |
| NCT03722407 | Phase II | Ruxolitinib | Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion | Active, not recruiting | USA | 0 |
| NCT03746041 | Phase I | Abaloparatide + Bevacizumab | A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes | Completed | USA | 0 |
| NCT03770429 | Phase I | Ceralasertib | AZD6738 for Patients With Progressive MDS or CMML | Active, not recruiting | USA | 0 |
| NCT03807063 | Phase I | Rimiducid Rivogenlecleucel | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Withdrawn | USA | 0 |
| NCT03814005 | Phase I | Azacitidine + MLN4924 | A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic Impairment | Completed | USA | ESP | 0 |
| NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
| NCT03896269 | Phase I | CPX-351 | CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
| NCT03912064 | Phase I | Ipilimumab | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | Active, not recruiting | USA | 0 |
| NCT03922100 | Phase Ib/II | NMS-P088 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | Terminated | ITA | FRA | ESP | 0 |
| NCT04016116 | Phase II | Pembrolizumab + Ruxolitinib Pembrolizumab | Dual PD-1 and JAK2 Inhibition in Hematological Malignancies | Withdrawn | USA | 0 |
| NCT04041050 | Phase I | Navitoclax Navitoclax + Ruxolitinib | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | Active, not recruiting | USA | TUR | SWE | ITA | HRV | GBR | FRA | ESP | DEU | BGR | BEL | 3 |
| NCT04139434 | Phase I | LP-108 | Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | Completed | USA | ESP | 0 |
| NCT04140487 | Phase Ib/II | Azacitidine + Gilteritinib + Venetoclax | Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Recruiting | USA | 0 |
| NCT04146038 | Phase II | Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | Completed | USA | 0 |
| NCT04160052 | Phase Ib/II | Azacitidine + Venetoclax | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
| NCT04167917 | Phase I | NTX-301 | NTX-301 in MDS/AML | Active, not recruiting | USA | 0 |
| NCT04239157 | Phase II | Azacitidine + Canakinumab | Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
| NCT04256317 | Phase II | ASTX030 ASTX030 + Azacitidine + Venetoclax ASTX030 + Azacitidine ASTX030 + Azacitidine + Cedazuridine | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) (AZTOUND) | Recruiting | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | 0 |
| NCT04264806 | Phase II | Azacitidine + Cusatuzumab Azacitidine | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) | Withdrawn | TUR | ITA | GBR | FRA | ESP | DEU | CHE | BRA | AUS | 2 |
| NCT04266301 | Phase III | Azacitidine Azacitidine + Sabatolimab | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2) | Terminated | USA | TUR | NLD | LTU | LBN | ITA | ISR | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 15 |
| NCT04372433 | Phase I | Azacitidine + IO-202 IO-202 Azacitidine + IO-202 + Venetoclax | IO-202 as Monotherapy and IO-202 Plus Azacitidine +/- Venetoclax in Patients in AML and CMML | Completed | USA | 0 |
| NCT04409639 | Phase II | Cobimetinib | Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO) | Active, not recruiting | USA | 0 |
| NCT04487106 | Phase II | Azacitidine + Trametinib + Venetoclax | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | Completed | USA | 0 |
| NCT04493138 | Phase Ib/II | Azacitidine + Quizartinib | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | Recruiting | USA | 0 |
| NCT04522895 | Phase II | Enasidenib | IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT | Completed | DEU | 0 |
| NCT04550442 | Phase Ib/II | Azacitidine + Venetoclax | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Active, not recruiting | USA | 0 |
| NCT04581512 | Phase Ib/II | EP0042 Azacitidine + EP0042 + Venetoclax | Study to Evaluate the Safety and Tolerability of EP0042 | Recruiting | NLD | GBR | AUS | 0 |
| NCT04609826 | Phase I | JNJ74856665 Azacitidine + JNJ74856665 JNJ74856665 + Venetoclax | A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Completed | GBR | FRA | ESP | 1 |
| NCT04655755 | Phase Ib/II | Decitabine and Cedazuridine + Venetoclax | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Active, not recruiting | USA | 0 |
| NCT04708054 | Phase II | Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | Recruiting | USA | 0 |
| NCT04730258 | Phase Ib/II | CFI-400945 CFI-400945 + Decitabine Azacitidine + CFI-400945 | A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML, MDS or CMML (TWT-202) | Active, not recruiting | USA | CAN | 1 |
| NCT04734990 | Phase Ib/II | Azacitidine + Seclidemstat | Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
| NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
| NCT04937166 | Phase I | Azacitidine + DSP107 + Venetoclax | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies | Terminated | USA | 0 |
| NCT04964518 | Phase I | APG-2575 + Azacitidine | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | Unknown status | USA | AUS | 0 |
| NCT05024994 | Phase II | E7820 | A Study of E7820 in People With Bone Marrow (Myeloid) Cancers | Completed | USA | 0 |
| NCT05030675 | Phase I | Fostamatinib | Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents | Completed | USA | 0 |
| NCT05107856 | Phase I | PRT1419 | A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies | Terminated | USA | 0 |
| NCT05178342 | Phase II | CA-4948 | Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS) | Terminated | DEU | 0 |
| NCT05209152 | Phase I | AMG 176 + Azacitidine AMG 176 | AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia | Terminated | USA | 0 |
| NCT05282459 | Phase Ib/II | Enasidenib | Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation | Completed | USA | 0 |
| NCT05342584 | Phase I | Cytarabine + Daunorubicin + Venetoclax | Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS (Venetoclax AML) | Recruiting | USA | 0 |
| NCT05365035 | Phase II | Azacitidine + Venetoclax Cladribine + Cytarabine + Venetoclax | A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | Recruiting | USA | 0 |
| NCT05428969 | Phase Ib/II | Azacitidine + FP-1305 Azacitidine + FP-1305 + Venetoclax | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB) | Active, not recruiting | USA | GBR | FIN | 0 |
| NCT05455294 | Phase I | Decitabine + Navitoclax + Venetoclax | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | Active, not recruiting | USA | 0 |
| NCT05549661 | Phase I | Onvansertib | Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
| NCT05600894 | Phase II | Decitabine and Cedazuridine Decitabine and Cedazuridine + Venetoclax | Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm With Excess Blasts | Active, not recruiting | USA | CAN | 0 |
| NCT05636514 | Phase I | Decitabine and Cedazuridine + Defactinib | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (CELESTIAL-MDS) | Recruiting | AUS | 0 |
| NCT05732103 | Phase Ib/II | CTX-712 | A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes | Recruiting | USA | 0 |
| NCT05768711 | Phase II | Azacitidine + Venetoclax | Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR) (AVENHIR) | Active, not recruiting | FRA | 0 |
| NCT05787496 | Phase I | NC525 | A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms | Terminated | USA | 0 |
| NCT05823571 | Phase I | Itacitinib | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | Active, not recruiting | USA | 0 |
| NCT05933070 | Phase I | INKmune | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL) | Terminated | GRC | GBR | 0 |
| NCT06071624 | Phase I | CD4CAR | Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. | Recruiting | USA | 0 |
| NCT06085638 | Phase Ib/II | Azacitidine + Tamibarotene + Venetoclax Azacitidine + Tamibarotene | Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia | Withdrawn | 0 | |
| NCT06159491 | Phase Ib/II | Azacitidine + Pacritinib | Pacritinib in CMML | Recruiting | USA | 0 |
| NCT06218628 | Phase I | Pacritinib + Talazoparib | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | Recruiting | USA | 0 |
| NCT06284460 | Phase Ib/II | ASTX029 ASTX029 + Decitabine and Cedazuridine | Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms | Withdrawn | USA | 0 |
| NCT06502145 | Phase I | Azacitidine + ORY-1001 | Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome | Recruiting | USA | 0 |
| NCT06523556 | Phase Ib/II | Axatilimab Axatilimab + Azacitidine | Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
| NCT06543381 | Phase I | Olutasidenib | Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant | Recruiting | USA | 0 |
| NCT06563804 | Phase Ib/II | S227928 + Venetoclax S227928 | A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML | Terminated | USA | FRA | FIN | DEU | AUS | 1 |
| NCT06566742 | Phase II | Olutasidenib | A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. | Recruiting | USA | 0 |
| NCT06597734 | Phase II | Decitabine and Cedazuridine + Olutasidenib Azacitidine + Olutasidenib Decitabine + Olutasidenib | A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm | Recruiting | USA | 0 |
| NCT06630221 | Phase II | Eltrombopag | Eltrombopag As a Novel Therapeutic Approach for Low-risk MDS and CMML with TET2 Mutations | Recruiting | USA | 0 |
| NCT06661915 | Phase II | Decitabine and Cedazuridine Decitabine and Cedazuridine + ORY-1001 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | Recruiting | USA | 0 |
| NCT06668584 | Phase Ib/II | Olutasidenib | A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients with IDH1-mutated Myeloid Malignancies | Recruiting | USA | 0 |
| NCT06712810 | Phase I | Adrixetinib | Q702 for the Treatment of Patients with Hematologic Malignancies | Recruiting | USA | 0 |
| NCT06904066 | Phase I | Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL | Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies | Recruiting | USA | 0 |
| NCT06930651 | Phase Ib/II | Cyclophosphamide + Decitabine + Dexamethasone + Fludarabine TGFBR2 KO CAR27/IL-15 NK cells | A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies | Recruiting | USA | 0 |
| NCT06950034 | Phase I | STX-0712 | A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | Recruiting | USA | 0 |
| NCT06994676 | Phase I | CBX-250 | A Study of CBX-250 in Participants With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (CROSSCHECK-001) | Recruiting | USA | 0 |
| NCT07006688 | Phase I | Ivosidenib | A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment | Not yet recruiting | ESP | BRA | AUS | 1 |
| NCT07064122 | Phase Ib/II | AZD2962 | A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) | Recruiting | USA | GBR | ESP | AUS | 3 |
| NCT07128381 | Phase Ib/II | Axatilimab + Ruxolitinib Axatilimab | Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | Recruiting | USA | 0 |
| NCT07270978 | Phase I | CD33 FPBMC | Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS (AML-MDS 001) | Recruiting | USA | 0 |